BTIG Maintains Buy on Exact Sciences, Lowers Price Target to $70
Portfolio Pulse from Benzinga Newsdesk
BTIG analyst Mark Massaro maintains a Buy rating on Exact Sciences (NASDAQ:EXAS) but lowers the price target from $80 to $70.

June 27, 2024 | 5:43 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
BTIG analyst Mark Massaro maintains a Buy rating on Exact Sciences but lowers the price target from $80 to $70.
The maintained Buy rating suggests continued confidence in the company's prospects, but the lowered price target indicates a more cautious outlook on its short-term performance. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100